ANI PHARMACEUTICALS INC Quarterly Amortization of Intangible Assets in USD from Q2 2012 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Ani Pharmaceuticals Inc quarterly/annual Amortization of Intangible Assets history and growth rate from Q2 2012 to Q3 2024.
  • Ani Pharmaceuticals Inc Amortization of Intangible Assets for the quarter ending September 30, 2024 was $13.9M, a 4.51% increase year-over-year.
  • Ani Pharmaceuticals Inc Amortization of Intangible Assets for the twelve months ending September 30, 2024 was $53.3M, a 3.5% increase year-over-year.
  • Ani Pharmaceuticals Inc annual Amortization of Intangible Assets for 2023 was $52.3M, a 5.66% increase from 2022.
  • Ani Pharmaceuticals Inc annual Amortization of Intangible Assets for 2022 was $49.5M, a 18.4% increase from 2021.
  • Ani Pharmaceuticals Inc annual Amortization of Intangible Assets for 2021 was $41.8M, a 4.76% increase from 2020.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $53.3M $13.9M +$600K +4.51% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $52.7M $13M +$200K +1.56% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $52.5M $13M +$200K +1.56% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $52.3M $13.4M +$800K +6.35% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $51.5M $13.3M +$800K +6.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 $50.7M $12.8M +$900K +7.56% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $49.8M $12.8M +$300K +2.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 $49.5M $12.6M +$700K +5.88% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $48.8M $12.5M +$2.4M +23.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $46.4M $11.9M +$1.8M +17.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $44.6M $12.5M +$2.8M +28.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $41.8M $11.9M +$2.1M +21.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $39.7M $10.1M $0 0% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $39.7M $10.1M +$100K +1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $39.6M $9.7M -$300K -3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $39.9M $9.8M +$1.4M +16.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-09
Q3 2020 $38.5M $10.1M +$1.7M +20.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-01
Q2 2020 $36.8M $10M +$1.6M +19% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $35.2M $10M -$5M -33.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $40.2M $8.4M +$400K +5% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-15
Q3 2019 $39.8M $8.4M +$500K +6.33% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $39.3M $8.4M +$500K +6.33% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $38.8M $15M +$7.1M +89.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $31.7M $8M +$1.3M +19.4% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-11
Q3 2018 $30.4M $7.9M +$1.1M +16.2% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $29.3M $7.9M +$1.1M +16.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $28.2M $7.9M +$1.5M +23.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $26.7M $6.7M +$1.1M +19.6% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $25.6M $6.8M +$1.1M +19.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $24.5M $6.8M +$1.1M +19.3% Mar 31, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $23.4M $6.4M +$2M +45.5% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $21.4M $5.6M +$3.7M +195% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 $17.7M $5.7M +$3.8M +200% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 $13.9M $5.7M +$4.5M +375% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $9.4M $4.4M +$3.2M +267% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 $6.2M $1.9M +$800K +72.7% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-27
Q3 2015 $5.4M $1.9M +$900K +90% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 $4.5M $1.2M +$600K +100% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
Q1 2015 $3.9M $1.2M +$600K +100% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-05
Q4 2014 $3.3M $1.1M +$726K +194% Oct 1, 2014 Dec 31, 2014 10-K 2017-03-02
Q3 2014 $2.57M $1M +$800K +400% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-03
Q2 2014 $1.77M $600K +$587K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-04
Q1 2014 $1.19M $600K +$587K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-05
Q4 2013 $600K $374K Oct 1, 2013 Dec 31, 2013 10-K 2016-02-23
Q3 2013 $200K +$188K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-10
Q2 2013 $13K* +$500 Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-07
Q1 2013 $13K* Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q3 2012 $12.5K* Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-07
Q2 2012 $12.5K* Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.